Stockscreener 앱 받기
2.625
0.94%
-0.025
시간 외 거래:
2.63
0.005
+0.19%
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
What analysts say about Aytu BioPharma Inc. stockDynamic profit opportunities - PrintWeekIndia
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN
What risks could impact Aytu BioPharma Inc. stock performanceHigh-velocity capital appreciation - jammulinksnews.com
What drives Aytu BioPharma Inc. stock priceExplosive trading growth - Autocar Professional
Aytu BioPharma Inc. Stock Analysis and ForecastPhenomenal trading returns - PrintWeekIndia
What analysts say about Aytu BioPharma Inc. stock outlookJaw-dropping returns - jammulinksnews.com
Is Aytu BioPharma Inc. a good long term investmentConsistent high-performance stocks - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru
Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru
How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser
Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World
Aytu Boosts Liquidity with Eclipse Loan Extension - MSN
Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World
Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus
Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener
Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - ACCESS Newswire
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire
Aytu BioPharma Lands $13M Financing Deal to Launch Revolutionary Depression Drug in $22B Market - Stock Titan
Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks
2.82%
0.27%
자본화:
|
볼륨(24시간):